重庆锐恩医药

Chongqing Ruien Biopharmaceutical (Ruien Biotech) is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer and autoimmune diseases. Founded in 2020 and based in Chongqing, China, the company leverages proprietary platforms to engineer regulatory T cells (Treg) and effector T cells (CAR-T). Its lead program, RE-101, is an umbilical cord blood-derived Treg therapy currently in Phase 1 clinical trials for Graft-versus-Host Disease (GvHD). Additionally, Ruien is advancing RE-001, a CAR-T therapy targeting Glypican-3 for the treatment of solid tumors like hepatocellular carcinoma. The company is backed by prominent investors including Hillhouse Capital's GL Ventures and Legend Capital. Ruien Biotech aims to address significant unmet medical needs by translating advanced immunology research into transformative clinical treatments.